|
|
|
|
||
-$1.05 EPS Expected for Prothena Co. PLC (PRTA) This Quarter08/28/2018 Wall Street brokerages forecast that Prothena Co. PLC (NASDAQ:PRTA) will announce earnings of ($1.05) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Prothena’s earnings, with the highest EPS estimate coming in at ($0.99) and the lowest estimate coming in at ($1.12). Prothena reported earnings per share of ($1.37) during the same quarter last year, which suggests a positive year-over-year growth rate of 23.4%. The company is expected to report its next earnings results on Tuesday, November 6th. On average, analysts expect that Prothena will report full-year earnings of ($4.43) per share for the current year, with EPS estimates ranging from ($4.54) to ($4.28). For the next year, analysts expect that the firm will post earnings of ($2.00) per share, with EPS estimates ranging from ($2.70) to ($0.85). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Prothena. Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. Prothena had a negative net margin of 21,884.38% and a negative return on equity of 46.42%. The firm had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.22 million. PRTA has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Prothena in a research note on Wednesday, August 8th. Zacks Investment Research raised shares of Prothena from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Wednesday, May 16th. BidaskClub raised shares of Prothena from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Oppenheimer reissued a “hold” rating on shares of Prothena in a research report on Friday, May 25th. Finally, Barclays lowered shares of Prothena from an “equal weight” rating to an “underweight” rating and set a $12.00 price target on the stock. in a research report on Monday, May 21st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. Prothena has a consensus rating of “Hold” and a consensus price target of $45.91. Prothena stock opened at $14.98 on Tuesday. Prothena has a 1-year low of $10.43 and a 1-year high of $70.00. The firm has a market capitalization of $582.02 million, a price-to-earnings ratio of -3.68 and a beta of 2.70. Hedge funds have recently made changes to their positions in the business. Xact Kapitalforvaltning AB purchased a new position in shares of Prothena in the first quarter worth about $210,000. LPL Financial LLC purchased a new position in shares of Prothena in the first quarter worth about $210,000. Aperio Group LLC purchased a new position in shares of Prothena in the first quarter worth about $222,000. Oppenheimer & Co. Inc. purchased a new position in shares of Prothena in the first quarter worth about $284,000. Finally, Millennium Management LLC purchased a new position in shares of Prothena in the fourth quarter worth about $338,000. About Prothena Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. For more information about research offerings from Zacks Investment Research, visit Zacks.com
|
return to message board, top of board |